List of Diagnostics Companies in Utah - 12

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays. ARUP is an Equal Opportunity Employer M/F/D/V and supports a drug-free environment. Scammers have been posing as ARUP recruiters to target jobseekers using fraudulent email addresses and social media accounts. ARUP recruiters will only contact you with legitimate offers by calling from 800-522-2787 or 801-583-2787 or emailing from an address ending in @aruplab.com. Read our full fraud statement on aruplab.com/careers

With more than 25 years of molecular experience, BioFire Diagnostics, LLC (now bioMérieux) sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. As BioMérieux’s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. BioFire Diagnostics has produced the easiest, fastest, and most comprehensive multiplex PCR testing available: the BioFire® FilmArray® System. The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. Whether you’re trying to determine optimal therapy for a septic patient or pinpoint which respiratory pathogen is making a young child sick, the BioFire System can provide definitive answers—fast.

Culmination is changing the world by discovering better health. We provide unparalleled value to health care organizations by unlocking biological data and enriching it with clinical, claims, and genomic data. We are on a journey to radically improve everyone's future health care experience. Culmination Bio will become the trusted source for health care insights and for generating discoveries that improve people’s lives.

ELITechGroup MDx, part of Bruker Corporation, is a leading provider of molecular diagnostics solutions, designed to meet the diverse and growing needs of laboratories worldwide. Headquartered in Turin, Italy, at ELITechGroup SpA, it serves as a key center for manufacturing, logistics, and business operations, making it one of the most prominent molecular biology hubs in Europe. Over the years, ELITechGroup MDx has developed a comprehensive suite of PCR technologies, including the revolutionary Minor Groove Binder (MGB). In 2016, ELITechGroup revolutionized molecular diagnostics with the introduction of ELITe InGenius, its first fully automated sample-to-result (S2R) system. Since then, the company has continued to expand the platform's capabilities, offering nearly 60 CE-IVD parameters and validating over 20 different sample matrices. Building on this success, ELITechGroup launched ELITe BeGenius in 2021, its second S2R platform, further solidifying its commitment to delivering superior workflow efficiency and guaranteed performance. With a robust pipeline of assays, instruments, and software, the company ensures that laboratories remain at the cutting edge of molecular diagnostics. All its products meet the highest global quality and regulatory standards and are fully compliant with the latest IVD regulations. ELITechGroup MDx is certified by DEKRA Certification BV and operates under a stringent quality management system in compliance with ISO 9001:2015 and EN ISO 13485:2016 standards according to the Medical Device Single Audit Program (MDSAP). In addition to its extensive product portfolio, ELITechGroup MDx provides expert technical support, including training, on-site assistance, and customized solutions from sample to result, ensuring that laboratories receive the highest level of service and performance.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.

Over 100 million Americans have either a pre-chronic illness, or a disease and the majority don’t even know it. Early detection, intervention and timely personal monitoring matters; but, improving wellbeing requires consumer interactions to be easy, convenient and fit naturally into their daily “life flow.” Medic.Life is a unique biotech startup focused on blending miniaturized assay systems, medical IoT, AI and mobile into a waste analyzer platform – a smart toilet – resolving pain points for everyday users and providers. Within 2 years, our technology will be found in clinics, senior care, primary care, pharmacies, retail outlets, and homes, while generating mountains of personal health data. As such, Medic is really a data company with a sophisticated user interface that captures, analyzes and trends vital health indicators every time our toilets are used and notifies users when anomalies are detected. It’s like having a Medic at your disposal. Medic.Life has a strong IP position with 60 patents granted and more than 90 pending so far. We are working with over 20 partners for our onboard science center (microfluidics, lab on chip, proprietary sensors) and seek to double that number in the 2020-21 timeframe. If you have miniaturized technology to analyze urine, feces, vitals, body composition and circulation, then please contact us.

NuView Life Sciences is a clinical stage precision oncology company. The Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor is over-expressed on the surface of a wide range of cancer types at the onset of oncogenesis. NuView's NV-VPAC1 small molecule binding agent designed to identify and bind to the VPAC receptors has been utilized in clinical trials for binary in vitro and in vivo of confirmation of cancer. The NV-VPAC1 agent can be utilized to deliver existing therapeutics and new alpha and beta emitters. NuView will pair existing imaging and therapeutic radionuclides with NuViews proprietary agent and provide a Theranostics solution for patients and clinicians.

nView medical, based in Salt Lake City, UT, is a startup whose mission is to make surgery safer, faster, and consistently accurate. nView develops imaging technology — bringing breakthrough AI solutions for image creation, image processing, and image visualization to surgery and interventional radiology. nView medical backers include the National Science Foundation (NSF), the National Institutes of Health (NIH), the State Of Utah, the National Capital Consortium for Pediatric Device Innovation, MedTech Innovator, HealthTech Arkansas, Dr. Kevin Foley, M.D., and Fusion Fund (Palo Alto, CA). Its founder, Cristian Atria, has had a progressive career with GE Healthcare in positions that range from development engineer to general manager with P&L responsibility. He has successfully assisted start-up and public companies with technology transfers, licensing, product development, regulatory approvals, and commercialization.

ScyTek Laboratories, Inc. a Utah, USA corporation involved in the manufacture of diagnostic reagents Special Stains, Antibodies, Hematology, Microbiology, Hematoxlyn

Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Our vision is to deliver pivotal information to physicians early in pregnancy to help them to improve the health of their patients and reduce costs of healthcare delivery. The PreTRM® Test reports to a physician the individualized risk of premature birth, enabling earlier proactive interventions in patients with higher risk. We're also developing a robust pipeline of innovative tests focused on other complications of pregnancy, including preeclampsia, gestational diabetes, growth restriction, and others. Learn more about our values, culture, and open positions on our website.

Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors. Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy. Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.